^
    20h
    SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=396, Not yet recruiting, Shanghai Chest Hospital
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ROS1 fusion
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Enshuxing (enlonstobart)
    21h
    XTX301-01: XTX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, Xilio Development, Inc. | Trial completion date: Feb 2027 --> Sep 2028 | Trial primary completion date: Feb 2027 --> Sep 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • MSI-H/dMMR • ALK fusion • ROS1 fusion • BRCA mutation • NTRK fusion
    |
    efarindodekin alfa (XTX301)
    1d
    EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway. (PubMed, Cancer Discov)
    Moreover, we observed that KRASG12C/EML4-ALK tumor cells kept under constant pressure with KRASG12C inhibitors exhibit sensitivity to single-agent ALK inhibitors, suggesting a potential for rationally designed sequential treatments. Mechanistically, EML4-ALK bypasses KRASG12C inhibition by activating wild-type RAS, highlighting an additional therapeutic opportunity for multi-selective RAS inhibitors under clinical investigation.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    KRAS mutation • ALK fusion • RAS wild-type
    6d
    Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential. (PubMed, Front Oncol)
    This case highlights the metastatic potential of ALK-rearranged unclassified mesenchymal neoplasms, particularly those exhibiting a tyrosine kinase phenotype (co-expression of S100 and CD34), supporting their classification within the intermediate, rarely metastasizing category according to soft tissue tumor stratification principles. It further emphasizes the need for heightened clinical vigilance and thorough surgical management, which may influence long-term outcomes.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule)
    |
    ALK rearrangement • ALK fusion
    9d
    A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment (PubMed, Zhongguo Fei Ai Za Zhi)
    This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment, suggesting that the two can coexist as dual drug resistance mechanisms. Re-biopsy combined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy..
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    Tagrisso (osimertinib)
    9d
    Case report: first-line lorlatinib in metastatic lung adenocarcinoma with a novel WIPF1-ALK and EML4-ALK dual fusion. (PubMed, Transl Lung Cancer Res)
    The achievement of over 24 months of disease control underscores lorlatinib's potent activity against these complex molecular profiles. Our findings highlight the importance of recognizing and targeting rare ALK fusion variants-even when coexisting with other ALK rearrangements and resistance-associated mutations and expand the therapeutic landscape of precision oncology for advanced NSCLC.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
    |
    TP53 mutation • ALK rearrangement • ALK fusion
    |
    Lorbrena (lorlatinib)
    12d
    Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi)
    13d
    Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=152, Not yet recruiting, The Third Xiangya Hospital of Central South University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • EGFR L858R • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • HER-2 exon 20 mutation • NTRK fusion
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    16d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    16d
    SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, University of Washington | Initiation date: Jun 2026 --> Sep 2026
    Trial initiation date • Checkpoint inhibition
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    SX-682 • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    17d
    Uterine inflammatory myofibroblastic tumor: a clinicopathological and molecular genetic analysis of eight cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    The patient was treated with the oral targeted drug crizotinib and died of multiple organ failure 18 months after surgery...UIMT and EIMS that exhibit aggressive behavior typically possess a greater number of genetic alterations. The abnormal expression of p53 or p16 protein, when combined with clinicopathological parameters, can serve as indicators for predicting the adverse biological behavior of tumors.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • ANK2 (Ankyrin 2)
    |
    TP53 mutation • ALK positive • ATM mutation • ALK rearrangement • ALK fusion
    |
    Xalkori (crizotinib)
    18d
    Brief Report: The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the 10th Edition TNM Classification. (PubMed, J Thorac Oncol)
    This study suggests that common molecular alterations in lung cancer exhibit prognostic value within specific stages, and notably, TP53, KRAS and ALK alterations hold the potential to modify the current staging system. These findings provide a valuable reference for the forthcoming 10th Edition TNM staging system.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK fusion • ALK mutation